Managing early multiple sclerosis

Practitioner

Volumn 242, Issue 1586, 1998, Pages 400-404

  Jordan, Nigel ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STEROID;

ANALGESIA; GENERAL PRACTICE; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; REVIEW; TRANSCUTANEOUS NERVE STIMULATION;

ANALGESIA; FAMILY PRACTICE; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; REFERRAL AND CONSULTATION; STEROIDS; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION;

EID: 0032057669     PISSN: 00326518     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Phadke JG, Downie AW. Epidemiology of multiple sclerosis in the north-east (Grampian Region) of Scotland - an update. J Epidemiol Community Health 1987;41:5-13
2. Roberts MHW, Martin JP, Mclellan DL et al. The prevalence of multiple sclerosis in the Southampton and South West Hampshire Health Authority. J Neurol Neurosurg Psychiatry 1991;54:55-59
3. Standards of heathcare for people with MS. Joint document by the MS Society of GB and Northern Ireland and the National Hospital for Neurology and Neurosurgery. Sept 1997
4. Jacobs D, Cookfair DL, Rudick RA et al. Intramuscular Interferon β- 1a for disease progression in Relapsing MS. Ann Neurol 1996;39:285-294
5. Interferon β-1b MS Study Group. Interferon β-1b is effective in relapsing-remitting MS.I. Clinical results of a mullicentre randomised double-blind, placebo-controlled trial. Neurology 1993;43:655-661
6. Johnson KP, Brookes BR, Cohen JA et al. Copolymer-1 reduces relapse rate and improved disability in relapsing-remitting MS. Results for a phase III multicentre, double-blind, placebo-controlled trial. Neurology 1995;45:1268-1276
7. Fazekas F, Deisenhammer D, Strasser Fuch S et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting MS. Lancet 1997;349:583-589